PYCR1: A Potential Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma

Wang, Huanyu; Mao, Weilin; Lou, Wenhui; Jin, Dayong; Wu, Wenchuan; Wang, Dansong; Kuang, Tiantao; Rong, Yefei; Xu, Xuefeng; Zhang, Lei

doi:10.7150/jca.61498



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2022; 13(5):1501-1511. doi:10.7150/jca.61498 This issue Cite

Research Paper

PYCR1: A Potential Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma

Huanyu Wang¹, Weilin Mao^2,3, Wenhui Lou^2,3, Dayong Jin^2,3, Wenchuan Wu^2,3, Dansong Wang^2,3, Tiantao Kuang^2,3, Yefei Rong^2,3, Xuefeng Xu^2,3✉, Lei Zhang^2,3✉

1. Department of General Surgery, Xuhui District Central Hospital, Shanghai, China.
2. Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
3. Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.

Citation:

Wang H, Mao W, Lou W, Jin D, Wu W, Wang D, Kuang T, Rong Y, Xu X, Zhang L. PYCR1: A Potential Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma. J Cancer 2022; 13(5):1501-1511. doi:10.7150/jca.61498. https://www.jcancer.org/v13p1501.htm

Other styles

Abstract

Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignant tumor with an extremely poor prognosis in digestive tumors. Pyrroline-5-carboxylate reductase 1 (PYCR1) plays an important role in tumor development. Therefore, we aimed to explore the effect of PYCR1 on the growth of PDAC cells.

Methods: Tumor tissues and adjacent normal pancreatic tissues were collected from 89 patients with PDAC. And immunohistochemistry (IHC) was used to analyze the expression level of PYCR1 in both. RNA interference was used to inhibit the expression of PYCR1 in PANC- 1 and AsPC-1 cells. After infection, the expression of PYCR1 protein was detected by Western blot. The proliferation and growth of PDAC cells were detected by Celigo analysis, MTT, and clone formation assay. Cell apoptosis was analyzed by flow cytometry. Furthermore, the effect of PYCR1 interference on tumor growth was evaluated in vivo through injecting tumor cells subcutaneously into nude mice.

Results: The expression of PYCR1 in pancreatic cancer tissues was significantly higher than in paired adjacent normal pancreatic tissues (P <0.01). In vitro, the downregulation of PYCR1 expression significantly inhibited the cell proliferation and colony formation, and increased apoptosis in PANC-1 cells and AsPC-1 cells compared with the shCtrl group (P <0.01). And in vivo, PYCR1 interference also significantly inhibited tumor growth both in the tumor volume and weight.

Conclusion: PYCR1 interference was able to inhibit cell proliferation and promote cell apoptosis of pancreatic cancer. The PYCR1 may serve as a potential therapeutic and prognostic biomarker for the treatment of pancreatic cancer.

Keywords: PYCR1, Pancreatic ductal adenocarcinoma, Prognosis

Citation styles

APA

Wang, H., Mao, W., Lou, W., Jin, D., Wu, W., Wang, D., Kuang, T., Rong, Y., Xu, X., Zhang, L. (2022). PYCR1: A Potential Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma. Journal of Cancer, 13(5), 1501-1511. https://doi.org/10.7150/jca.61498.

ACS

Wang, H.; Mao, W.; Lou, W.; Jin, D.; Wu, W.; Wang, D.; Kuang, T.; Rong, Y.; Xu, X.; Zhang, L. PYCR1: A Potential Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma. J. Cancer 2022, 13 (5), 1501-1511. DOI: 10.7150/jca.61498.

NLM

CSE

Wang H, Mao W, Lou W, Jin D, Wu W, Wang D, Kuang T, Rong Y, Xu X, Zhang L. 2022. PYCR1: A Potential Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma. J Cancer. 13(5):1501-1511.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.